tetano
Editor, Senior Moderator
DNA Cell Biol
. 2022 Nov 17.
doi: 10.1089/dna.2022.0293. Online ahead of print.
Evaluating the Relationship Between Antiphospholipid Antibodies and COVID-19 Severity
Alireza Sadeghi[SUP] 1 [/SUP], Masumeh Hasanlu[SUP] 1 [/SUP], Abdolamir Feyzi[SUP] 2 [/SUP], Kamyar Mansori[SUP] 3 [/SUP], Samad Ghodrati[SUP] 4 [/SUP], Negin Parsamanesh[SUP] 5 [/SUP]
Affiliations
Abstract
Coronavirus 2 (COVID-19) has emerged as a new global pandemic, causing severe acute respiratory syndrome. Furthermore, the existence of antiphospholipid (APL) antibodies (Abs) and ultimately patient death may be linked to the occurrence of thrombotic events in patients with COVID-19. We aimed to investigate if there was a link between the presence of APL Abs and the severity of COVID-19 disease in patients at the Vali-Asr Hospital in Zanjan from June to July 2021. Real-time PCR was used to diagnose COVID-19 in 76 hospitalized patients. A total of 38 patients were hospitalized in the internal medicine ward and another 38 people were admitted to the intensive care unit of the Vali-Asr Educational Hospital in Iran's Zanjan region. Lupus anticoagulant (LAC) detection was done using the dilute Russell viper venom time method, and tests for anticardiolipin (ACL) Abs, IgG and IgM, and anti-beta2 glycoprotein 1 Abs, IgG and IgM, were done on blood and plasma samples of linked patients using the enzyme-linked immunosorbent assay technique. SPSS 24 was used to analyze data. Our findings showed that the presence of LAC was associated with disease severity in COVID-19 patients (p = 0.001). However, there was no significant relationship between APL Abs and mortality in patients affected with COVID-19. The evaluation of APL Abs, particularly LAC, in COVID-19 patients appears to be helpful in predicting the severity of the disease.
Keywords: COVID-19; antiphospholipid antibody; disease severity.
. 2022 Nov 17.
doi: 10.1089/dna.2022.0293. Online ahead of print.
Evaluating the Relationship Between Antiphospholipid Antibodies and COVID-19 Severity
Alireza Sadeghi[SUP] 1 [/SUP], Masumeh Hasanlu[SUP] 1 [/SUP], Abdolamir Feyzi[SUP] 2 [/SUP], Kamyar Mansori[SUP] 3 [/SUP], Samad Ghodrati[SUP] 4 [/SUP], Negin Parsamanesh[SUP] 5 [/SUP]
Affiliations
- PMID: 36394439
- DOI: 10.1089/dna.2022.0293
Abstract
Coronavirus 2 (COVID-19) has emerged as a new global pandemic, causing severe acute respiratory syndrome. Furthermore, the existence of antiphospholipid (APL) antibodies (Abs) and ultimately patient death may be linked to the occurrence of thrombotic events in patients with COVID-19. We aimed to investigate if there was a link between the presence of APL Abs and the severity of COVID-19 disease in patients at the Vali-Asr Hospital in Zanjan from June to July 2021. Real-time PCR was used to diagnose COVID-19 in 76 hospitalized patients. A total of 38 patients were hospitalized in the internal medicine ward and another 38 people were admitted to the intensive care unit of the Vali-Asr Educational Hospital in Iran's Zanjan region. Lupus anticoagulant (LAC) detection was done using the dilute Russell viper venom time method, and tests for anticardiolipin (ACL) Abs, IgG and IgM, and anti-beta2 glycoprotein 1 Abs, IgG and IgM, were done on blood and plasma samples of linked patients using the enzyme-linked immunosorbent assay technique. SPSS 24 was used to analyze data. Our findings showed that the presence of LAC was associated with disease severity in COVID-19 patients (p = 0.001). However, there was no significant relationship between APL Abs and mortality in patients affected with COVID-19. The evaluation of APL Abs, particularly LAC, in COVID-19 patients appears to be helpful in predicting the severity of the disease.
Keywords: COVID-19; antiphospholipid antibody; disease severity.